Company: NIVFW
Filing Date: 2025-06-03
Form Type: 424B3
Source: 0001213900-25-050825
Chunk: 230

Company: NewGenIvf Group Ltd
Filing Date: 2025-06-03
Form: 424B3
Chunk 230
---
rogacy, and ancillary caring services,
for total consideration of $15,000. The acquisition enhances the Company’s position in healthcare fertility sector. The transaction
was accounted for as a business combination under ASC 805, Business Combinations.

At the acquisition date, Bi Clinic had not yet
commenced revenue-generating activities but had established the necessary regulatory approvals and licensing framework to operate as an
IVF and surrogacy service provider. These approvals, along with the Company’s planned integration of medical personnel and operational
processes, provide the necessary inputs and substantive processes required to meet the definition of a business under ASC 805.

Since Bi Clinic had no other assets or liabilities,
the entire purchase price was allocated to intangible assets, specifically the IVF license and regulatory approvals. No goodwill was recognized
in connection with the transaction.

As Bi Clinic had no prior operations, its financial
results have been included in the consolidated financial statements from the acquisition date, with no historical revenue or expenses
impacting the Company’s consolidated results. Pro forma financial information has been omitted, as the acquisition is not considered
material to the Company’s financial results.

NOTE 22 — SUBSEQUENT EVENTS

The Company evaluated subsequent
events and transactions that occurred after the balance sheet date up to the date that the financial statements were issued. Based upon
this review, other than as described below, the Company did not identify any subsequent events that would have required adjustment or
disclosure in the financial statements.

On February 11, 2025, the
Company carried out a 1-for-20 reverse stock split of its issued and unissued shares. The effect of the reverse stock split was to consolidate
every 20 issued and unissued shares into one share.

On February 24, 2025, the
Company entered into a Consulting Services Agreement with A SPAC (Holdings) Group Corp (“ASPAC”), pursuant to which the Company
engaged ASPAC for the provision of certain consulting services. It was agreed that the Company would provide consideration in the form
of cash and shares. On March 3, 2025, the Company issued the 150,000 (equivalent to 15,000 post Second Reverse Stock Split) Class A Ordinary
Shares to ASPAC.

On February 27, 2025, the Company received a confirmation from Nasdaq
that its application to transfer its listing to the Nasdaq Capital Market had been approved and that the Company’s securities were
transferred to the Nasdaq